Report: Slow growth expected for molecular imaging market

08/30/2013 | MolecularImaging.net

A GlobalData report released this month says 14 or more molecular imaging agents are in clinical development, with U.S. and European approvals for GE Healthcare's F-18 flutemetamol, Piramal Imaging's F-18 florbetaben and Lantheus Medical Imaging's F-18 flurpiridaz expected over the next three years. The market is being fueled by the rising interest in personalized medicine, but barriers such as clinical trial rules and the high cost of creating novel imaging agents remain. Additionally, an expected isotope shortage, reimbursement issues and other large-scale issues are keeping the industry from growing faster, the report says.

View Full Article in:

MolecularImaging.net

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX